Marinus Pharmaceuticals is developing the allopregnanolone analog Ganaxolone as a treatment for epilepsy and other seizure disorders. Its most advanced program is a multinational P3 trial of patients with refractory focal onset seizures. The drug is also being tested in patients with Fragile X syndrome and in girls with epilepsy due to PCDH19 mutation. The […]
Chimera Research Group Catalyst Summary for February 2015
At the end of each month Chimera Research Group provides you with a monthly summary of notable catalysts that have been completed during the past month. February 2015: GILD provided detailed results of their Phase 3 once-daily single tablet regimen of tenofovir alafenamide (TAF) for the treatment of HIV-1 infection. The data showed that it was found […]
Pfenex: Biosimilar Enthusiasm Is High
San Diego’s Pfenex Inc. is riding the market’s enthusiasm for biosimilars, molecules that although not considered identical, can be automatically substituted for biologic drugs. Previously considered immune to generic competition, recent regulatory changes have cleared the path to entry for copycats of so-called large molecule compounds. A looming patent cliff in 2020 puts about $100 […]
Quick update: The IBB – Negative Divergence
iShares Nasdaq Biotechnology (IBB) – Nasdaq As tweeted several time last and early this week, signs of weakness in the IBB Signs of weakness in the $IBB ..Start forming a Bearish “Rising Wedge” ..only if breaking down the lower line & 50MA pic.twitter.com/MPmn1DNF2T — Joe (@GantosJ) February 2, 2015 The “Rising Wedge” is a bearish pattern, […]
Chimera Research Group Catalyst Summary for January 2015
At the end of each month Chimera Research Group provides you with a monthly summary of notable catalysts that have been completed during the past month. JANUARY 2015: 1) Bristol-Myers Squibb Company (NYSE:BMY) announced that their Phase 3 CheckMate-017 trial evaluating Opdivo versus docetaxel for the treatment of refractory squamous cell non-small cell lung cancer […]
Revisiting the Bubble Debate
With this week’s moves in the market and with the JP Morgan Healthcare conference finished, I think its time to bring up the debate again about whether or not biotech may be in a bubble. While most are familiar with the outstanding sector performance, lets just put it into context a bit. Since the March […]
CBSTZ: New developments for Cubist CVR
A quick update on CBSTZ the Cubist CVR. Today Cubist filed an 8-K notifying CVR holders that it intends to purchase all the CVRs at $0.059225 on February 2, 2015. This is known as a “Failure Purchase Notice”. Below is a link to the 8-K: http://www.sec.gov/Archives/edgar/data/912183/000110465915000010/a14-26868_48k.htm This outcome is listed as a possibility in the […]
Chimera Research Group Catalyst Summary for December 2014
At the end of each month Chimera Research Group provides you with a monthly summary of notable catalysts that have been completed during the past month. DECEMBER 2014: 1) AbbVie (NYSE:ABBV) announced that the FDA approved Viekira Pak (ombitasvir/paritaprevir/ritonavir & dasabuvir), their next generation oral treatment for patients with chronic genotype 1 (GT1) hepatitis C […]
CBSTZ: a low probability, high impact special situation
This week started with a merger Monday. Cubist Pharmaceuticals agreed to be acquired by Merck & Company for $9.5B including assumption of debt. CBST traded like one would expect on Monday, just below the offer price. However, a Contingent Value Right (CVR) with the ticker CBSTZ traded up to $0.081 on Monday, which represents a […]
BMY – A Bull Flag Breakout or A Head Fake
Bristol-Myers Squibb Company (BMY) -NYSE Interesting price action since October 15th, after touching the support line $47.52 and bouncing back to start a new uptrend, we were looking to reach at least the last 52-weeks high at $57.49 . But BMY’s price spike even higher reaching new 52-weeks high $59.03 on October 30th after reporting […]
Quick Note on GWPH
GWPH has been on one huge rollercoaster. After climbing back from $61 in mid-October to $80 in late November, it has given up 15% in just the last 3 trading days, falling back to $68 as the rest of biotech surges following their morning Q3 conference call. Perhaps investors had been expecting more detailed data […]
Quick Survery
We are constantly looking for was to improve Chimera and ensure that everyone is getting value for their money. As part of this process, we are looking for feedback from you all. Please take the time to fill out this quick survey, so we can learn where we need to improve and what you find […]
What to Look For at ASH 2014
The year is nearly over, though it feels like scientific conferences never end. December 6th marks the last big Cancer meeting of the year- then we turn the page to 2015. We’ve put together a list of over a dozen companies presenting at ASH, along with data we believe investors will be looking for: AGIO […]
ABBV Survey Results [Free Content]
Earlier today on twitter there was a robust debate about the weakness seen in GILD and how this is related to fears on the upcoming competition from ABBV/ENTA. It seemed clear that there was a debate over the ultimate discount that ABBV was going to offer when compared to the GILD regime. While everyone had […]
GWPH: A Compelling Story
GW Pharma’s Tuesday morning R&D meeting looked pretty good. Efficacy data were released for 58 patients with full 12-weeks of epidiolex treatment- 40 of whom have been treated for 16-weeks. The total safety database consisted of 151 patients who have received any drug. Data from this larger pool of 58 patients- double that from the […]
Biotech Survey Results- Number 1
This is the first report on what I want to be a fairly regular set of surveys. I want to keep the surveys short to maximize participation as the more responders the more relevant the results. I also plan on regularly doing the question on market direction and top three, so over time we will […]
Sarepta at World Muscle Society: Follow-up
The only new data provided by Sarepta were various measures of lung function, including, including %predicted MIP, MEP, and FVC; all of which demonstrated stabilization through 144 weeks for the 12 boys in the treated population. Individual patient data were once again provided, this time at the 144 week time point. As the trend has […]
CNAT – A Quick Chart Update
Conatus Pharmaceuticals Inc. (CNAT) –Nasdaq CNAT was trading within a downtrend channel since June 16th after reaching the high of $9.90, finding a base around the $6.00 weekly support line as mentioned several time at Chimera’s twitter private feed and was moving side way in a consolidation mode for two weeks. J: $CNAT bouncing 8.5% […]
SRPT- A Squeeze In The Making
Sarepta Therapeutics, Inc. (SRPT)-Nasdaq Sarepta is preparing for a busy 4th quarter ahead of the NDA submission as confirmed again by the company’s CEO Chris Garabedian during the Morgan Stanley Healthcare Conference on September 10th. We received guidance in April from the FDA that outlined a very clear path-forward, which resulted in a plan […]
SRPT and SAGE: Quick Notes
Nice 36-month Natural history study (or “Pane Study”) in Duchenne published essentially confirming what’s pretty much already known- that boys age 7 and over decline more rapidly than those under 7. They had previously reported 24 month results. This study and the Eteplirsen study are largely comparable. Average age of the older boys subgroup are […]
